• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » How Effective Is Tramadol for Opioid Withdrawal?

How Effective Is Tramadol for Opioid Withdrawal?

September 1, 2017
Taylor Noriega, PharmD candidate (2018).
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Taylor Noriega, PharmD candidate (2018). Ms. Noriega has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Dunn K et al, JAMA Psychiatry 2017. doi:10.1001/jamapsychiatry.2017.1838. [Epub ahead of print]

Opioid withdrawal protocols often rely on a buprenorphine taper, but other medications are regularly used either in addition to or in the place of buprenorphine. In particular, tramadol ER, a mild opiate, may be effective and was recently studied at Johns Hopkins University School of Medicine.

A total of 103 participants with opioid dependence were enrolled in this study comparing tramadol ER (n = 36), buprenorphine (n = 31), and clonidine (n = 36) for opioid withdrawal. Overall, 88 of the subjects (85.4%) were male, 43 (41.7%) were white, and average age was 29 years. Past 30-day use of heroin was reported by 96 (93.2%) of the ­participants vs. 49 (47.5%) who reported using prescription opioids in that time period (some used both).

People in the study were randomized to three arms: tapering with tramadol (up to 600 mg/day), clonidine (up to 0.8 mg/day), or buprenorphine (up to 8 mg/day). Following the week-long taper, all participants were crossed over to placebo for a week, then were given a naloxone challenge to verify successful withdrawal.

The trial used several measures, including the Subjective Opiate Withdrawal Scale (SOWS) completed by participants, the Clinical Opiate Withdrawal Scale (COWS) completed by clinicians, pupil diameter, and concomitant medication use (mostly over-the-counter meds for GI symptoms, pain, and sleep).

Researchers found that tramadol ER was more effective than clonidine and comparable to buprenorphine in terms of patient retention and withdrawal symptom suppression during the 7-day detox period. Patients treated with clonidine and tramadol used more concomitant supportive medications during the taper than those on buprenorphine, though the number of meds used was low (0–2) across all three groups.

CATR’s Take
Based on this study, tramadol seems like an attractive option—you don’t need a buprenorphine waiver, and it may be more effective than clonidine. Considering it is an opioid agonist, it’s no surprise that tramadol helps alleviate withdrawal symptoms. But the doses of tramadol used were particularly high (usual dose in pain is 50–200 mg/day), whereas the doses of buprenorphine were relatively low (usual dose in detox is 8–16 mg/day). Still, if buprenorphine is not an option, then tramadol could be worth considering. Just be cautious of drug interactions, especially with serotonergic agents (increased seizure risk).
Addiction Treatment
KEYWORDS addiction pharmacology-tips research-update substance-abuse
Taylor Noriega, PharmD candidate (2018).

More from this author
www.thecarlatreport.com
Issue Date: September 1, 2017
SUBSCRIBE NOW
Table Of Contents
Take The CME Post-Test for Detox, CATR, September/October 2017
Cannabis Use Disorder Treatment
Kratom: A Primer for Clinicians
How Effective Is Tramadol for Opioid Withdrawal?
Detox: An Overview
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • Substance_Use_Sites.jpeg
    Addiction Treatment

    Supervised Drug Consumption Sites

    Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.